Holen Sie sich die Stockscreener-App
4.01
0.50%
0.02
Vorhandelsmarkt:
4.11
0.10
+2.49%
Schlusskurs vom Vortag:
$3.99
Offen:
$4.05
24-Stunden-Volumen:
198.87K
Relative Volume:
1.53
Marktkapitalisierung:
$70.73M
Einnahmen:
$52.55M
Nettoeinkommen (Verlust:
$-23.69M
KGV:
-4.266
EPS:
-0.94
Netto-Cashflow:
$-15.29M
1W Leistung:
+33.67%
1M Leistung:
-22.14%
6M Leistung:
+104.59%
1J Leistung:
+102.53%
1-Tages-Spanne:
$3.72
$4.20
1-Wochen-Bereich:
$2.76
$4.20
52-Wochen-Spanne:
$1.3003
$6.22
Exagen Inc Stock (XGN) Company Profile
Firmenname
Exagen Inc
Sektor
Branche
Telefon
(760) 560-1501
Adresse
1261 LIBERTY WAY, VISTA, CA
Vergleichen Sie XGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.01 | 70.73M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-05 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-04-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Eingeleitet | Cowen | Outperform |
| 2019-10-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Exagen Inc Aktie (XGN) Neueste Nachrichten
Exagen Gains 28%, Insider Trades Reap Benefit - Yahoo Finance
The 26% return this week takes Exagen's (NASDAQ:XGN) shareholders one-year gains to 102% - Simply Wall St
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? - MSN
Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests - Lupus Foundation of America
Exagen’s (XGN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reaffirms "Overweight" Rating for Exagen (NASDAQ:XGN) - MarketBeat
Exagen Inc. Secures Conditional NY State Approval for New - GlobeNewswire
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis - The Bakersfield Californian
Exagen Achieves Record $55.8M Revenue, Gets NY Approval for New Lupus & RA Biomarker Tests - StockTitan
Exagen (NASDAQ:XGN) Given New $7.00 Price Target at Canaccord Genuity Group - Defense World
Exagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Short Interest in Exagen Inc. (NASDAQ:XGN) Grows By 36.5% - Defense World
Exagen Inc. (NASDAQ:XGN) Short Interest Up 36.5% in December - MarketBeat
Exagen (NASDAQ:XGN) Stock Price Up 1.4%Time to Buy? - MarketBeat
Exagen (NASDAQ:XGN) Trading 1.4% Higher – Still a Buy? - Defense World
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - Simply Wall St
Learn to Evaluate (XGN) using the Charts - Stock Traders Daily
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewswire
Exagen Hits Major Milestone: 1 Million AVISE Tests Revolutionize Autoimmune Disease Diagnosis - StockTitan
Exagen stock soars to 52-week high, hits $4.97 - Investing.com
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com India
Exagen stock soars to 52-week high, hits $4.88 amid robust gains By Investing.com - Investing.com South Africa
Exagen stock soars to 52-week high, hits $4.88 amid robust gains - Investing.com Canada
Wasatch Advisors LP Sells 272,054 Shares of Exagen Inc. (NASDAQ:XGN) - MarketBeat
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Nigeria
Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada
Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St
Exagen stock soars to 52-week high, hits $3.79 - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK
Exagen president and CEO John Aballi buys $68,297 in stock By Investing.com - Investing.com Canada
Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com
What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Exagen Inc-Aktie (XGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):